The pandemic has resulted in a change in consumer lifestyles, with an increased focus on preventive healthcare remedies leading to a surge in demand for immunity-positioned supplements, including Ayurvedic medicines and products, as consumers pursue different ways to combat the virus.
Four others MD of Ramdev-promoted Patanjali Ayurved Acharya Balkrishna; Director of National Institute of Medical Sciences and Research (NIMS), Jaipur, B S Tomar; his son Anurag Tomar; and senior scientist Anurag Varshney have also been named in the FIR, he said.
"The licence for the drug was obtained on the basis of the traditional knowledge and experience related to the medicinal virtues of Ashwagandha, Giloy and Tulsi," Patanjali spokesperson S K Tijarawala said.
Three stockmarket experts give their best picks for the New Year.
Modi said Ayurveda is India's heritage whose expansion entails the welfare of humanity and all Indians will be happy to see that the country's traditional knowledge is making other countries prosperous.
While Ramdev claimed that Ayurved-based 'Coronil and Swasari' medicine have shown 100 per cent favourable results during clinical trials on COVID-19 infected patients except those on a life support system, the Ayush Ministry sought from the company detailed report on composition, testing and other data of the drugs.
Wellness expert Roopashree Sharma answers your health queries.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances